Secologanin vs Meloxicam
Mechanistic comparison of Secologanin Tryptamine Alkaloids Compounds formed by condensation of secologanin with tryptamine resulting in and Meloxicam based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
8
Shared Targets
30%
Jaccard Similarity
26%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
Secologanin and Meloxicam share 8 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.296 means 30% of the combined target set is bound by both compounds. The IDF-weighted score of 0.260 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.